Compare PCLA & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCLA | QNRX |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 10.1M |
| IPO Year | 2025 | N/A |
| Metric | PCLA | QNRX |
|---|---|---|
| Price | $0.33 | $13.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 60.1M | 92.9K |
| Earning Date | 02-13-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,065,197.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.26 | N/A |
| 52 Week Low | $0.12 | $5.01 |
| 52 Week High | $9.80 | $41.80 |
| Indicator | PCLA | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 49.33 |
| Support Level | $0.29 | $13.42 |
| Resistance Level | $0.35 | $14.49 |
| Average True Range (ATR) | 0.08 | 1.23 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 55.78 | 77.95 |
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.